HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dauerman, H. L. Search for Related Content PubMed PubMed Citation Articles by Dauerman, H. L. Related Collections Related Article

Treatment of Stent Restenosis

Moving Beyond Momentum^_*

University of Vermont College of Medicine, Burlington, Vermont.

View larger version (32K): [in a new window]   Figure 1 Randomized clinical trials of treatment options for in-stent restenosis. The lowest angiographic restenosis rates reported to date are for drug-eluting stents as a treatment of in-stent restenosis. ARTIST (9) = Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial; BMS = bare metal stent; ISAR-DESIRE (19) = Intracoronary Stenting with Antithrombotic Regimen–Drug-Eluting Stents for In-Stent Restenosis; PES = paclitaxel-eluting stent; RESCUT (10) = Restenosis Cutting Balloon Evaluation Trial; RIBS-I (11) = Restenosis Intrastent: Balloon Angioplasty Versus Elective Bare Metal Stenting; RIBS II (18) = Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting; SES = sirolimus-eluting stent; START (15) = Sr90 Treatment of Angiographic Restenosis; WRIST (12) = Washington Radiation for In-Stent Restenosis Trial.